2126 — JW (Cayman) Therapeutics Co Cashflow Statement
0.000.00%
- HK$813.35m
- HK$75.11m
- CNY173.86m
Annual cashflow statement for JW (Cayman) Therapeutics Co, fiscal year end - December 31st, CNY millions except per share, conversion factor applied.
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | PROSPECTUS | ARS | ARS | ARS | ARS |
Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
Status: | Final | Final | Final | Final | Final |
Net Income/Starting Line | -633 | -1,664 | -702 | -846 | -768 |
Depreciation | |||||
Amortisation | |||||
Non-Cash Items | 444 | 1,359 | 34.8 | 231 | 233 |
Unusual Items | |||||
Other Non-Cash Items | |||||
Changes in Working Capital | -17.1 | 20.1 | 58.1 | -9.12 | 36.9 |
Change in Accounts Receivable | |||||
Change in Inventories | |||||
Change in Prepaid Expenses | |||||
Change in Other Assets | |||||
Change in Accrued Expenses | |||||
Other Operating Cash Flow | |||||
Cash from Operating Activities | -189 | -261 | -561 | -537 | -398 |
Capital Expenditures | -114 | -130 | -137 | -101 | -14.6 |
Purchase of Fixed Assets | |||||
Purchase / Acquisition of Intangibles | |||||
Other Investing Cash Flow Items | -3.49 | 38.3 | 0 | -23.5 | 24.5 |
Sale of Business | |||||
Sale of Fixed Assets | |||||
Other Investing Cash Flow | |||||
Cash from Investing Activities | -118 | -91.9 | -137 | -124 | 9.9 |
Financing Cash Flow Items | 34.7 | -27.3 | -18.3 | -6.79 | -12.4 |
Other Financing Cash Flow | |||||
Net Issuance / Retirement of Stock | |||||
Net Issuance / Retirement of Debt | |||||
Cash from Financing Activities | 414 | 2,859 | -30.6 | 112 | 0.275 |
Foreign Exchange Effects | |||||
Beginning Cash Balance | |||||
Ending Cash Balance | |||||
Net Change in Cash | 121 | 2,376 | -796 | -451 | -377 |